[go: up one dir, main page]

PE20220487A1 - Anticuerpos anti-ms4a4a y metodos de uso de los mismos - Google Patents

Anticuerpos anti-ms4a4a y metodos de uso de los mismos

Info

Publication number
PE20220487A1
PE20220487A1 PE2022000171A PE2022000171A PE20220487A1 PE 20220487 A1 PE20220487 A1 PE 20220487A1 PE 2022000171 A PE2022000171 A PE 2022000171A PE 2022000171 A PE2022000171 A PE 2022000171A PE 20220487 A1 PE20220487 A1 PE 20220487A1
Authority
PE
Peru
Prior art keywords
region
hvr
seq
group
amino acid
Prior art date
Application number
PE2022000171A
Other languages
English (en)
Inventor
Jeonghoon Sun
Wei-Hsien Ho
Muhammad A Alhawagri
Philip Ling Kong
Herve Rhinn
Hua Long
Karpagam Srinivasan
Ananya Mitra
Daniel P Bermingham
Klaus-Dieter Heger
Santiago Viveros Salazar
Francesca Cignarella
Ilaria Tassi
Tina Schwabe
Angie Grace Yee
Arnon Rosenthal
Original Assignee
Alector Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alector Llc filed Critical Alector Llc
Publication of PE20220487A1 publication Critical patent/PE20220487A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Referida a un anticuerpo aislado que se une a una proteina MS4A4A, donde el anticuerpo comprende una region variable de cadena pesada y una region variable de cadena ligera, donde la region variable de cadena pesada comprende: una region HVR-H1 que comprende una secuencia de aminoacidos seleccionados de entre los grupos que consisten en los SEQ ID NO: 94, 108, 116, 146, 147, 308, y 311; una region HVR-H2 que comprende una secuencia de aminoacidos seleccionada del grupo que consiste en los SEQ ID NO:96, 97, 98, 99, 110, 111, 118, 119, 120, 121, 122, 149, 150, 151, 152, 153, 309, y 312; y una region HVR-H3 que comprende una secuencia de aminoacidos seleccionada de entre el grupo que consiste en los SEQ ID NO: 102, 100, 101, 102, 112, 123, 124, 125, 126, 127, 128, 129, 154, 310, y 313; y la region variable de cadena ligera comprende: una region HVR-L1 que comprende una secuencia de aminoacidos seleccionados del grupo que consiste en SEQ ID NO: 104, 103, 113, 130, 131, 132, 133, 134, 135, 136, 137, 138, 156, 157, 158, 314, y 317; una region HVR-L2 que comprende una secuencia de aminoacidos seleccionada de entre el grupo que consiste en SEQ ID NO.: 105, 106, 114, 139, 140, 141, 142, 143, 159, 160, 161, 315, y 318; y una region HVR-L3 que comprende una secuencia de aminoacidos seleccionada de entre el grupo que consiste en los SEQ ID NO:107, 115, 144, 145, 163, 316, y 319. Tambien esta referida a composiciones que comprenden los mencionados anticuerpos. Dicho anticuerpo es util en el tratamiento de enfermedades neurodegenerativas.
PE2022000171A 2019-07-31 2020-07-30 Anticuerpos anti-ms4a4a y metodos de uso de los mismos PE20220487A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962881187P 2019-07-31 2019-07-31
US201962892467P 2019-08-27 2019-08-27
US201962947449P 2019-12-12 2019-12-12
US202062960606P 2020-01-13 2020-01-13
US202063057142P 2020-07-27 2020-07-27
PCT/US2020/044335 WO2021022083A2 (en) 2019-07-31 2020-07-30 Anti-ms4a4a antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
PE20220487A1 true PE20220487A1 (es) 2022-04-04

Family

ID=72139691

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000171A PE20220487A1 (es) 2019-07-31 2020-07-30 Anticuerpos anti-ms4a4a y metodos de uso de los mismos

Country Status (18)

Country Link
US (2) US11667699B2 (es)
EP (1) EP4003519A2 (es)
JP (2) JP7612658B2 (es)
KR (1) KR20220058540A (es)
CN (2) CN119954954A (es)
AU (1) AU2020321969A1 (es)
BR (1) BR112022001733A2 (es)
CA (1) CA3145885A1 (es)
CL (1) CL2022000230A1 (es)
CO (1) CO2022000832A2 (es)
CR (1) CR20220078A (es)
EC (1) ECSP22015044A (es)
IL (1) IL289952A (es)
MX (1) MX2022001260A (es)
PE (1) PE20220487A1 (es)
PH (1) PH12022550239A1 (es)
TW (1) TWI874431B (es)
WO (1) WO2021022083A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021513328A (ja) 2018-01-31 2021-05-27 アレクター リミテッド ライアビリティ カンパニー 抗ｍｓ４ａ６ａ抗体及びその使用方法
WO2019152715A1 (en) 2018-01-31 2019-08-08 Alector Llc Anti-ms4a4a antibodies and methods of use thereof
CN119954954A (zh) 2019-07-31 2025-05-09 艾莱克特有限责任公司 抗ms4a4a抗体及其使用方法
WO2024026472A2 (en) * 2022-07-29 2024-02-01 Alector Llc Transferrin receptor antigen-binding domains and uses therefor
MA71628A (fr) * 2022-07-29 2025-05-30 Alector Llc Anticorps anti-gpnmb et leurs méthodes d'utilisation
WO2024086796A1 (en) 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies
WO2025096087A1 (en) 2023-10-30 2025-05-08 Regeneron Pharmaceuticals, Inc. Treatment of myeloid cell dysfunction with membrane spanning 4-domains a6a (ms4a6a) inhibitors

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0861893A3 (en) 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
AU7378096A (en) 1995-09-28 1997-04-17 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
JP4460155B2 (ja) 1997-12-05 2010-05-12 ザ・スクリプス・リサーチ・インステイチユート マウス抗体のヒト化
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
KR20020093029A (ko) 2000-04-11 2002-12-12 제넨테크, 인크. 다가 항체 및 그의 용도
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
AU2002251692A1 (en) 2000-12-08 2002-08-19 Duke University Identification of novel ms4a gene family members expressed by hematopoietic cells
EP1443961B1 (en) 2001-10-25 2009-05-06 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
AU2003236017B2 (en) 2002-04-09 2009-03-26 Kyowa Kirin Co., Ltd. Drug containing antibody composition
CN102911987B (zh) 2002-04-09 2015-09-30 协和发酵麒麟株式会社 基因组被修饰的细胞
US7749753B2 (en) 2002-04-09 2010-07-06 Kyowa Hakko Kirin Co., Ltd Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost
JPWO2003085118A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物の製造方法
GB0324888D0 (en) * 2003-10-24 2003-11-26 Novartis Ag Organic compounds
MXPA06011199A (es) 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
CN101001879A (zh) * 2004-06-14 2007-07-18 伊利诺伊大学董事会 与胎儿而非成体cd34+/cd36+细胞结合的抗体
KR20070034588A (ko) 2004-06-14 2007-03-28 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 Ｃｄ３４＋／ｃｄ３６＋ 태아 세포에는 결합하지만 성체세포에는 결합하지 않는 항체
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
SI2359834T1 (sl) 2006-03-15 2017-02-28 Alexion Pharmaceuticals, Inc. Zdravljenje pacientov,ki imajo paroksizmalno nočno hemoglobinurijo, z zaviralcem komplementa
CA2651567A1 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
US10118970B2 (en) 2006-08-30 2018-11-06 Genentech, Inc. Multispecific antibodies
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
EP2108701A1 (en) * 2008-04-10 2009-10-14 Ganymed Pharmaceuticals AG Methods involving MS4A12 and agents targeting MS4A12 for therapy, diagnosis and testing
ES2659764T3 (es) 2011-08-23 2018-03-19 Roche Glycart Ag Moléculas biespecíficas de unión a antígeno activadoras de linfocitos T
CN104774264B (zh) 2014-01-15 2018-09-14 上海易乐生物技术有限公司 抗人proBDNF单克隆抗体及其在疼痛中的作用
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
WO2017143036A1 (en) 2016-02-16 2017-08-24 President And Fellows Of Harvard College Modulators of ms4a activity
CN105759057A (zh) * 2016-04-12 2016-07-13 上海凯璟生物科技有限公司 一种检测阿尔兹海默综合症ms4a6a的干式免疫荧光试剂盒和制备方法
JP2021513328A (ja) 2018-01-31 2021-05-27 アレクター リミテッド ライアビリティ カンパニー 抗ｍｓ４ａ６ａ抗体及びその使用方法
WO2019152715A1 (en) 2018-01-31 2019-08-08 Alector Llc Anti-ms4a4a antibodies and methods of use thereof
CN119954954A (zh) 2019-07-31 2025-05-09 艾莱克特有限责任公司 抗ms4a4a抗体及其使用方法

Also Published As

Publication number Publication date
ECSP22015044A (es) 2022-03-31
CN114341181A (zh) 2022-04-12
JP2022542964A (ja) 2022-10-07
CL2022000230A1 (es) 2022-10-07
TW202120547A (zh) 2021-06-01
US11667699B2 (en) 2023-06-06
BR112022001733A2 (pt) 2022-06-28
PH12022550239A1 (en) 2022-12-19
WO2021022083A2 (en) 2021-02-04
JP7612658B2 (ja) 2025-01-14
MX2022001260A (es) 2022-04-18
CN119954954A (zh) 2025-05-09
CN114341181B (zh) 2025-01-07
US20210079074A1 (en) 2021-03-18
US20240076362A1 (en) 2024-03-07
KR20220058540A (ko) 2022-05-09
JP2025060826A (ja) 2025-04-10
EP4003519A2 (en) 2022-06-01
CO2022000832A2 (es) 2022-04-29
IL289952A (en) 2022-03-01
AU2020321969A1 (en) 2022-03-17
CA3145885A1 (en) 2021-02-04
TWI874431B (zh) 2025-03-01
CR20220078A (es) 2022-06-24
WO2021022083A3 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
PE20220487A1 (es) Anticuerpos anti-ms4a4a y metodos de uso de los mismos
PE20201186A1 (es) Anticuerpos antitau y metodos de uso
PE20210342A1 (es) Anticuerpos anti-sirpa y metodos de utilizacion de los mismos
PE20211863A1 (es) Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
AR102594A1 (es) ANTICUERPOS ANTI-IL-1b Y MÉTODOS DE USO
JP2020500538A5 (es)
PE20190630A1 (es) Anticuerpos de anti-tim-3
AR126019A1 (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
PE20212088A1 (es) Anticuerpos anti-tau y uso de los mismos
PE20200011A1 (es) ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
PE20150025A1 (es) Anticuerpos e inmunoconjugados contra ly6e y metodos de uso
MX387662B (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
AR103713A1 (es) Anticuerpos contra tau y sus usos
PE20120553A1 (es) Anticuerpos anti-fgfr3
AR102592A1 (es) Anticuerpos biespecíficos y métodos de uso en oftalmología
AR114281A1 (es) Anticuerpos anti-klk5 y métodos de uso
AR099855A1 (es) Anticuerpos hemaglutinina del virus antiinfluenza b y métodos de uso
ES2628108T3 (es) Anticuerpos multiespecíficos
RS52452B (en) Antibodies and Immunoconjugates and Their Use
PE20220392A1 (es) Moleculas de union a claudina-6 y usos de las mismas
AR069501A1 (es) Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
NZ626520A (en) Anti-lrp5 antibodies and methods of use
PE20150211A1 (es) Anticuerpos e inmunoconjugados anti-cd79b
PE20141562A1 (es) Anticuerpos anti-htra1 y metodos de uso